Search research articles
Contact Us
Filters
Showing results (151-160 of 177) with videos related to
Page
of 18
Sort By:
Nature Medicine
|
December 9, 2024
Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease
Violeta Raverdy, Federica Tavaglione, Estelle Chatelain, et al.
Journal of Pediatric Gastroenterology and Nutrition
|
June 30, 2026
ESPGHAN position paper on screening, diagnosis and investigation of paediatric metabolic dysfunction-associated steatotic liver disease
Jake P Mann, Sander Lefere, Maarten Buytaert, et al.
Cell Death and Differentiation
|
July 26, 2024
Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease
Cédric Peleman, Stig Hellemans, Geraldine Veeckmans, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 26, 2025
Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of MASLD
Yasaman Vali, Anne-Marieke van Dijk, Jenny Lee, et al.
The Lancet. Gastroenterology & Hepatology
|
September 26, 2024
Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study
Mathias Jachs, Aitor Odriozola, Fanny Turon, et al.
The New England Journal of Medicine
|
February 7, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, et al.
Contemporary Clinical Trials
|
October 12, 2020
The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease
Timothy Hardy, Kristy Wonders, Ramy Younes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2022
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma
Markus W Löffler, Stefania Gori, Francesco Izzo, et al.
Nature Reviews. Gastroenterology & Hepatology
|
October 28, 2021
Advancing the global public health agenda for NAFLD: a consensus statement
Jeffrey V Lazarus, Henry E Mark, Quentin M Anstee, et al.
The Lancet. Gastroenterology & Hepatology
|
March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study
Yasaman Vali, Jenny Lee, Jerome Boursier, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 177) with videos related to
Sort By:
Page
of 18
Nature Medicine
|
December 9, 2024
Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease
Violeta Raverdy, Federica Tavaglione, Estelle Chatelain, et al.
Journal of Pediatric Gastroenterology and Nutrition
|
June 30, 2026
ESPGHAN position paper on screening, diagnosis and investigation of paediatric metabolic dysfunction-associated steatotic liver disease
Jake P Mann, Sander Lefere, Maarten Buytaert, et al.
Cell Death and Differentiation
|
July 26, 2024
Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease
Cédric Peleman, Stig Hellemans, Geraldine Veeckmans, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 26, 2025
Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of MASLD
Yasaman Vali, Anne-Marieke van Dijk, Jenny Lee, et al.
The Lancet. Gastroenterology & Hepatology
|
September 26, 2024
Spleen stiffness measurement by vibration-controlled transient elastography at 100 Hz for non-invasive predicted diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a modelling study
Mathias Jachs, Aitor Odriozola, Fanny Turon, et al.
The New England Journal of Medicine
|
February 7, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, et al.
Contemporary Clinical Trials
|
October 12, 2020
The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease
Timothy Hardy, Kristy Wonders, Ramy Younes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2022
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma
Markus W Löffler, Stefania Gori, Francesco Izzo, et al.
Nature Reviews. Gastroenterology & Hepatology
|
October 28, 2021
Advancing the global public health agenda for NAFLD: a consensus statement
Jeffrey V Lazarus, Henry E Mark, Quentin M Anstee, et al.
The Lancet. Gastroenterology & Hepatology
|
March 23, 2023
Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study
Yasaman Vali, Jenny Lee, Jerome Boursier, et al.
Page
of 18